These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 16485889

  • 1. The incidence of recurrent herpes simplex and herpes zoster infection during treatment with arsenic trioxide.
    Nouri K, Ricotti CA, Bouzari N, Chen H, Ahn E, Bach A.
    J Drugs Dermatol; 2006 Feb; 5(2):182-5. PubMed ID: 16485889
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Herpes zoster during treatment with arsenic trioxide.
    Tanvetyanon T, Nand S.
    Ann Hematol; 2004 Mar; 83(3):198-200. PubMed ID: 15064871
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hyperleukocytosis from arsenic trioxide.
    Levy M, Wofford MM, Powell BL, McLean TW.
    Pediatr Blood Cancer; 2008 Jun; 50(6):1265-7. PubMed ID: 18300308
    [Abstract] [Full Text] [Related]

  • 7. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
    Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Neuwirth R, Anderson KC, Richardson PG.
    J Clin Oncol; 2008 Oct 10; 26(29):4784-90. PubMed ID: 18711175
    [Abstract] [Full Text] [Related]

  • 8. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
    Douer D, Tallman MS.
    J Clin Oncol; 2005 Apr 01; 23(10):2396-410. PubMed ID: 15800332
    [Abstract] [Full Text] [Related]

  • 9. Clinical activity of arsenic trioxide for the treatment of multiple myeloma.
    Munshi NC, Tricot G, Desikan R, Badros A, Zangari M, Toor A, Morris C, Anaissie E, Barlogie B.
    Leukemia; 2002 Sep 01; 16(9):1835-7. PubMed ID: 12200700
    [Abstract] [Full Text] [Related]

  • 10. [Arsenic trioxide: "a successful poison" in patients with acute promyelocytic leukemia].
    Lengfelder E, Schultheis B, Büchner T, Hehlmann R.
    Dtsch Med Wochenschr; 2007 Feb 16; 132(7):330-6. PubMed ID: 17286223
    [No Abstract] [Full Text] [Related]

  • 11. Differentiation syndrome with lethal lung injury after arsenic trioxide treatment for myelodysplastic syndrome.
    Ofran Y, Avivi I, Gesundheit B, Or R, Rowe JM, Zuckerman T.
    Am J Hematol; 2007 Apr 16; 82(4):332-3. PubMed ID: 17080434
    [No Abstract] [Full Text] [Related]

  • 12. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.
    Hussein MA, Saleh M, Ravandi F, Mason J, Rifkin RM, Ellison R.
    Br J Haematol; 2004 May 16; 125(4):470-6. PubMed ID: 15142117
    [Abstract] [Full Text] [Related]

  • 13. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
    Vey N, Bosly A, Guerci A, Feremans W, Dombret H, Dreyfus F, Bowen D, Burnett A, Dennis M, Ribrag V, Casadevall N, Legros L, Fenaux P.
    J Clin Oncol; 2006 Jun 01; 24(16):2465-71. PubMed ID: 16651646
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
    Schiller GJ, Slack J, Hainsworth JD, Mason J, Saleh M, Rizzieri D, Douer D, List AF.
    J Clin Oncol; 2006 Jun 01; 24(16):2456-64. PubMed ID: 16651647
    [Abstract] [Full Text] [Related]

  • 16. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
    Verstovsek S, Giles F, Quintás-Cardama A, Perez N, Ravandi-Kashani F, Beran M, Freireich E, Kantarjian H.
    Hematol Oncol; 2006 Dec 01; 24(4):181-8. PubMed ID: 16783836
    [Abstract] [Full Text] [Related]

  • 17. Solid tumors subsequent to arsenic trioxide treatment for acute promyelocytic leukemia.
    Au WY, Kumana CR, Lam CW, Cheng VC, Shek TW, Chan EY, Liu R, Kwong YL.
    Leuk Res; 2007 Jan 01; 31(1):105-8. PubMed ID: 16725199
    [Abstract] [Full Text] [Related]

  • 18. Clinical trials referral resource. Clinical trials with arsenic trioxide.
    Murgo AJ, McBee WL, Cheson BD.
    Oncology (Williston Park); 2000 Feb 01; 14(2):206, 211, 215-6 passim. PubMed ID: 10736809
    [No Abstract] [Full Text] [Related]

  • 19. Comparing two arsenic trioxide administration methods in APL therapy.
    Zhou J, Meng R, Yang BF.
    Chin Med J (Engl); 2004 Sep 01; 117(9):1411-3. PubMed ID: 15377438
    [No Abstract] [Full Text] [Related]

  • 20. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment.
    Au WY, Tam S, Kwong YL.
    Leuk Res; 2008 Feb 01; 32(2):357-8. PubMed ID: 17662385
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.